<DOC>
	<DOCNO>NCT00002783</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy surgery treat patient high-risk stomach cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Before After Surgery Treating Patients With Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy toxicity neoadjuvant cisplatin/fluorouracil ( CDDP/5-FU ) follow surgery follow adjuvant intraperitoneal floxuridine/leucovorin patient high-risk gastric cancer . II . Assess quality life cost-benefit ratio associate treatment . III . Evaluate sensitivity , specificity , overall stag accuracy laparoscopy without laparoscopic ultrasound predict resectability rate ( without neoadjuvant CDDP/5-FU ) , response chemotherapy , accuracy compare pathologic finding . IV . Correlate presence mutate vs. wild-type p53 suppressor oncogene endoscopic biopsy resect tumor specimens clinical outcome ( defined downstaging , failure pattern , disease-free overall survival ) patient treat without neoadjuvant CDDP/5-FU . OUTLINE : The follow acronym use : CDDP Cisplatin , NSC-119875 CF Leucovorin calcium , NSC-3590 5-FU Fluorouracil , NSC-19893 FUDR Floxuridine , NSC-27640 2-Drug Combination Chemotherapy follow Surgery follow Single-Agent Chemotherapy Drug Modulation . CDDP/5-FU ; follow total subtotal radical gastrectomy D2 dissection ; follow FUDR ; CF . PROJECTED ACCRUAL : A total 50 patient enter 2-2.5 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Microscopically confirm adenocarcinoma stomach gastroesophageal junction Reviewed Department Pathology participate institution Stage IIIV ( T2 , N12 , M0 T34 , N , M0 ) physical exam , CT , laparoscopy Potentially curable surgery Suspected sit metastasis proven M0 prior entry PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 60 % 100 % Hematopoietic : WBC least 4,000 Platelets least 150,000 Hepatic : Bilirubin le 2 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 50 mL/min BUN great 30 mg/dL Cardiovascular : No NYHA class III/IV status No active angina No myocardial infarction within 6 month No significant ventricular arrhythmia require medication No clinically significant conduction system abnormality Other : No serious intercurrent infection No nonmalignant medical illness uncontrolled precludes study participation No psychiatric disorder precludes inform consent No clinically significant auditory impairment No second malignancy within 5 year except : Basal cell skin cancer Carcinoma situ cervix No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>